Beck Mack & Oliver’s Teva Pharmaceuticals TEVA Stock Holding History

Beck Mack & Oliver’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-620,000	Closed	-$5.65M	–	172
2022 Q4	$5.65M	Buy	+620,000	New	+$5.41M	0.17%	64
2022 Q3	–	Sell	-7,350	Closed	-$2.15M	–	173
2022 Q2	$2.15M	Buy	7,350 +250	+4%	+$2.18K	0.06%	86
2022 Q1	$3.25M	Buy	7,100 +2,590	+57%	+$21.6K	0.08%	79
2021 Q4	$1.63M	Buy	4,510 +3,000	+199%	+$27.1K	0.04%	97
2021 Q3	$702K	Hold	1,510	–	–	0.02%	133
2021 Q2	$891K	Hold	1,510	–	–	0.02%	118
2021 Q1	$770K	Hold	1,510	–	–	0.02%	118
2020 Q4	$819K	Hold	1,510	–	–	0.03%	117
2020 Q3	$725K	Sell	1,510 -2,448	-62%	-$25.9K	0.03%	121
2020 Q2	$1.37M	Buy	3,958 +2,658	+204%	+$30.1K	0.05%	92
2020 Q1	$712K	Sell	1,300 -1,808	-58%	-$18.5K	0.03%	115
2019 Q4	$475K	Buy	+3,108	New	+$27.7K	0.02%	149
2019 Q3	–	Sell	-2,235	Closed	-$226K	–	219
2019 Q2	$226K	Buy	+2,235	New	+$26.9K	0.01%	198

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Beck Mack & Oliver's TEVA Position: Q1 2026 in Review

Beck Mack & Oliver reduced its Teva Pharmaceuticals (TEVA) stake by 0.45% in Q1 2026, selling an estimated $154K and leaving 1,051,700 shares worth $31.7M. The position accounts for 0.65% of the portfolio, ranked #37.

Beck Mack & Oliver first reported a position in TEVA in Q2 2013 and has held it in 41 quarters since. The position peaked at $71.7M in Q3 2021. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

Beck Mack & Oliver held 1,051,700 shares of Teva Pharmaceuticals worth $31.7M as of Q1 2026.
Beck Mack & Oliver sold 4,800 Teva Pharmaceuticals shares in Q1 2026, an estimated $154K.
Teva Pharmaceuticals made up 0.65% of Beck Mack & Oliver's portfolio in Q1 2026, its #37 holding.
Beck Mack & Oliver first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 41 quarters since.
Beck Mack & Oliver's Teva Pharmaceuticals position peaked at $71.7M in Q3 2021.
650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Beck Mack & Oliver's 13F filing for Q1 2026, filed 12 May 2026.